Verseon Corporation Result of Special Meeting & Board Appointment (1396U)
October 20 2017 - 1:00AM
UK Regulatory
TIDMVSN
RNS Number : 1396U
Verseon Corporation
20 October 2017
Press release October 20, 2017
Verseon Corporation
("Verseon" or the "Company")
Results of Special Shareholder Meeting and Appointment of Dr.
Robert W. Karr to the Board of Directors
FREMONT, Calif.-Verseon Corporation (AIM:VSN), a
technology-based pharmaceutical company, is pleased to announce
that Dr. Robert W. Karr was elected as a Non-Executive Class II
Director ("Director") of the Company, effective immediately, at the
Company's Special Shareholder Meeting ("Special Meeting") held on
October 19, 2017 at 14:00 PDT.
As detailed in the announcement of the Special Meeting made on
September 25, 2017, Dr. Karr has previously served in a range of
senior management roles in the pharmaceutical and biotech industry,
including Senior Vice President of R&D Strategy at Pfizer and
Chief Scientific Officer at Tioma Therapeutics. He brings to
Verseon broad expertise spanning drug discovery and development,
clinical trials, as well as investor relations and partnering
efforts.
Commenting on Dr. Karr's appointment, Adityo Prakash, Chief
Executive Officer said: "We are delighted to welcome Dr. Karr to
Verseon's Board of Directors. For many years he has helped shape
Verseon's drug programs as a member of our Scientific Advisory
Board, and we are excited that he has now agreed to serve as a
Non-Executive Director. Verseon is entering a significant period as
we prepare to advance some of our drug programs into clinical
trials. With his wealth of experience and unique understanding of
the global pharmaceutical industry, Dr. Karr will provide valuable
leadership and strategic insight."
"I am excited to join Verseon's Board of Directors," said Dr.
Karr. "I have supported the Company since its early years because I
recognized the potential impact of Verseon's disruptive platform on
drug discovery. The recent results across the Company's pipeline,
and in particular the progress toward clinical trials, show that
Verseon is realizing this potential. I look forward to working with
Verseon's interdisciplinary team."
Other Information
In relation to the appointment of Dr. Karr, the Company confirms
that there is no further information to be disclosed under
paragraph (g) of Schedule 2 of the AIM Rules for Companies save as
disclosed below:
Full Name: Robert William Karr
----------------------------- --------------------------
Age: 69
----------------------------- --------------------------
Current Directorships Tansna Therapeutics, Inc.
/ Partnership:
----------------------------- --------------------------
Previous Directorships Idera Pharmaceuticals,
/ Partnership in the past Inc.
5 years: Vasculox, Inc.
Antegrin Therapeutics
LLC
Mencuro Therapeutics,
Inc.
Medros, Inc.
----------------------------- --------------------------
Shareholding in the Company 185,264 shares
----------------------------- --------------------------
- Ends -
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Tina Schlafly 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Jamie +44 (0) 20
Hooper 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLFFVLIVLALID
(END) Dow Jones Newswires
October 20, 2017 02:00 ET (06:00 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024